Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symplmed Pharmaceuticals LLC

www.symplmed.com

Latest From Symplmed Pharmaceuticals LLC

FDA Starts 2015 As It Plans To Go On: A Spate Of Approvals, A Full Slate Of Possibilities

With more than 40 novel agents under FDA review – and seven approvals already – prospects are good for 2015 to be another stellar year for new molecular entity and novel biologic approvals. Supplemental indications with “breakthrough” designations and the first biosimilars could challenge the primacy of NMEs in the approval narrative.

BioPharmaceutical Regulation

FDA Starts 2015 As It Plans To Go On: A Spate Of Approvals, A Full Slate Of Possibilities

With more than 40 novel agents under FDA review – and six approvals already – prospects are good for 2015 to be another stellar year for new molecular entity and novel biologic approvals. Supplemental indications with “breakthrough” designations and the first biosimilars could challenge the primacy of NMEs in the approval narrative.

BioPharmaceutical Clinical Trials

FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod

Also, Rockwell’s iron deficiency treatment Triferic gains agency approval, but without a dose-sparing claim related to erythropoiesis-stimulating agents; Symplmed’s perindopril/amlodipine fixed-dose combination approved for hypertension.

BioPharmaceutical United States

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Symplmed Pharmaceuticals LLC
  • Senior Management
  • Erik C Emerson, Pres. & CEO
    Jeff Feldstein, MD, SVP, CMO
  • Contact Info
  • Symplmed Pharmaceuticals LLC
    Phone: (888) 552-9769
    5375 Medpace Way
    Cincinnati, OH 45227
    USA
UsernamePublicRestriction

Register